4:45 PM - 5:00 PM (EDT), Monday, June 5, 2023 ・ Session Room 104A
Leveragen is a genetic engineering company with technologies designed to revolutionize the discovery of biologic modalities for next-generation therapeutic and diagnostic applications. Harnessing CRISPR gene editing and chromosome engineering technologies, we have extensively modified the immunoglobulin heavy chain locus to generate the Singularity Sapiens mouse, which solely produces heavy chain antibodies from the complete human VH repertoire. Unlike conventional transgenic approaches, this targeted strategy eliminates all competing conventional antibodies, safeguards immunoglobulin gene regulation, and promotes normal B cell development and differentiation, resulting in robust immune responses and maximal antibody diversity. Employing an AI-powered, NGS-driven antibody discovery pipeline, we have generated a panel of fully human single domain antibodies against several therapeutic targets with superior affinity, stability, solubility, and modularity. This foundational platform can drastically accelerate the discovery of a broad range of biologic modalities such as nanobodies and multi-specific antibodies, as well as CAR-T and mRNA therapies.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Tools/Drug Development Support Tech
Lead Product in Development:
Humanized mice for single domain antibodies
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Founder and CEO
Leveragen, Inc.